# Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-appoints-mr-youchen-chen-and-dr-ian-y-liu-as-executive-directors
- Published: 2026-08-27T21:09:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other areas, today announced the appointment of Mr. Youchen Chen, Chief
Financial Officer, and Dr. Ian Y. Liu, Senior Vice President and Global Head of 
Legal, as Executive Directors of the Company, effective immediately. The appointments
further strengthen the alignment between the Company’s Board of Directors and management
team, providing strong leadership support for the Company’s global strategic execution
and sustainable growth.

Mr. Youchen Chen currently serves as Chief Financial Officer of Harbour BioMed and
is based in Hong Kong and Shanghai. As a key executive of the Company’s management
team, he is responsible for overseeing the Company’s global financial strategy, 
capital market strategy, investor relations, as well as strategic ecosystem development
and investment initiatives. Mr. Chen joined Harbour BioMed in 2023 and has progressively
assumed key responsibilities across finance, strategy, investor relations and corporate
development. He has played a pivotal role in leading a number of landmark strategic
transactions with global partners.

Mr. Youchen Chen has nearly 15 years of experience spanning global capital markets,
financial management, and business development in the biopharmaceutical industry.
Prior to joining Harbour BioMed, he served as Chief Financial Officer of a clinical-
stage radiopharmaceutical startup. Before that, he served as Vice President at Credit
Suisse China Investment Banking and Capital Market team, where he provided strategic
and capital markets advisory services to healthcare and tech companies across Greater
China regions. Prior to rejoining Credit Suisse China, he worked as Head of Corporate
Finance at Yidu Tech and Audit Assistant Manager at KPMG. Mr. Chen holds a bachelor’s
degree in law from Fudan University and an MBA from the McDonough School of Business
at Georgetown University.

Dr. Ian Y. Liu currently serves as Senior Vice President and Global Head of Legal
at Harbour BioMed and is based in the United States. He oversees the Company’s global
legal affairs, with a focus on ensuring legal and regulatory compliance across its
businesses and transactions. He also leads the Company’s global intellectual property
strategy and oversees major litigation matters.

Dr. Liu has more than 20 years of experience spanning global legal and government
affairs, as well as biopharmaceutical R&D and operations. Prior to joining Harbour
BioMed, he worked at internationally recognized law firms, including Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP and K&L Gates LLP, where he gained extensive experience
in patent applications, litigation, and due diligence. In the corporate legal affairs
sector, he previously served as Head of Legal and Government Affairs at Simcere 
Pharmaceutical, and as Global Head of Legal and Head of U.S. Operations at BREAS,
a subsidiary of Fosun Pharma, where he demonstrated strong expertise in navigating
complex legal matters, commercial negotiations, and international operations. Dr.
Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester
Polytechnic Institute, and a J.D. from Suffolk University Law School.

Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed,
commented: "We are very pleased to welcome Mr. Youchen Chen and Dr. Ian Y. Liu to
the Company’s Board of Directors. Their outstanding achievements and deep expertise
in their respective fields have already made a significant impact on our Company.
The appointment of both as Executive Directors is a strong recognition of their 
professional capabilities and leadership contributions. We are confident that in
their new roles, they will bring even greater diversity and depth of insight to 
the Company’s strategic decision-making, further propelling Harbour BioMed to new
heights in global innovation and sustainable growth."

Mr. Youchen Chen, Chief Financial Officer and Executive Director of Harbour BioMed,
stated: "It is a great honor to further participate in corporate governance and 
strategic decision-making in my new capacity as Executive Director. Since joining
Harbour BioMed, I have had the privilege of witnessing and contributing to the Company’s
rapid global development and the execution of multiple key strategic partnerships.
In the future, I look forward to working closely with the Board and the management
team to further optimize the Company’s financial and capital market strategies and
drive long-term value creation, while contributing to Harbour BioMed’s ambitious
goal of becoming a leading global platform-based biopharmaceutical group by 2028."

Dr. Ian Y. Liu, Senior Vice President, Global Head of Legal, and Executive Director
of Harbour BioMed, said: "It is a true privilege to continue serving Harbour BioMed
as an Executive Director. The Company has always stood at the forefront of innovative
drug discovery and development. In the areas of global legal compliance and intellectual
property strategy, I will continue to leverage my professional expertise to provide
solid legal protection and strategic support for the Company’s globalization efforts
and innovative growth."

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS^(TM)) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx^(TM) AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS^(TM), a single B-cell cloning
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](https://www.harbourbiomed.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors ](http://www.prnasia.com/story/archive/5033917_CN33917_0?rand=184833)